Rapid reportAnatomical localization of leucine-rich repeat kinase 2 in mouse brain
Section snippets
Tissue
All animal procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC) and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996. Every effort was made to minimize the number of animals used and their suffering.
Four adult FVB/N mice (Taconic, Germantown, NY, USA) were killed and brains were excised rapidly. Half the brain was frozen on dry ice for sagittal
Results
The anatomical localization of mRNA hybridization signal was identical for each of the five probes tested, thus confirming the specificity of the oligonucleotides to the target LRRK2 mRNA sequence (see Fig. 1 for a comparison between LRRK2 exon 10/11 and exon 15 signal). The competition control hybridizations for each probe yielded no signal (see Fig. 2). LRRK2 mRNA signal intensity was always found to be highest in the striatum and the olfactory tubercle (Fig. 2). In addition, robust signal
Discussion
In this study we find that in mouse brain, LRRK2 mRNA is most highly expressed in the striatum, olfactory tubercle and the cortex, which are key regions involved in dopaminergic transmission. The nigrostriatal pathway projects from the dopamine-synthesizing neurons of the substantia nigra pars compacta to striatum. Involved in motor control, it is this pathway that degenerates in PD (reviewed by Vallone et al., 2000). The mesolimbic dopaminergic pathway originates in the midbrain ventral
Acknowledgments
This work was supported by the Parkinson’s Disease Foundation (fellowship award to H.M.) and the Morris. K. Udall Parkinson’s Disease Centre of Excellence.
References (11)
- et al.
Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport
Neuroscience
(1992) - et al.
Retrograde axonal transport of neurotensin in the dopaminergic nigrostriatal pathway in the rat
Neuroscience
(1990) - et al.
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonismevidence of a common founder across European populations
Am J Hum Genet
(2005) - et al.
LRRK2 R1441G in Spanish patients with Parkinson’s disease
Neurosci Lett
(2005) - et al.
Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease
Neuron
(2004)
Cited by (102)
Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease
2022, Neurobiology of DiseaseAge-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum
2018, Neurobiology of AgingCitation Excerpt :At the same time, quantification of dopaminergic neurons from young and old cohort 2 showed no increased neurodegeneration compared to the untreated contralateral side for any vector (Supplementary Fig. S9B), indicating that inefficient retrograde transport was the reason underlying the limited nigral transgene expression. As a consequence of this finding, we focused our further histopathological analyses on the striatum, in which LRRK2 is endogenously expressed at higher levels than in the SNpc (Galter et al., 2006; Higashi et al., 2007a,b; Mandemakers et al., 2012; Melrose et al., 2006; Taymans et al., 2006; West et al., 2014). Co-staining for LRRK2 and neuronal or glial markers (2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase) for oligodendrocytes/myelinated fibers, GFAP for astrocytes, Iba1 for microglial cells) showed that our HC-AdVs transduced all neural cell types, however with different efficiencies.
Leucine-rich repeat kinase 2 is a regulator of B cell function, affecting homeostasis, BCR signaling, IgA production, and TI antigen responses
2016, Journal of NeuroimmunologyCitation Excerpt :These findings suggest that the immune system could play important roles in the neuronal dysfunction and pathology of PD. A number of studies of human and rodent brain have demonstrated that LRRK2 is expressed in various regions, including the substantia nigra, putamen, cortex, and cerebellum (Paisan-Ruiz et al. 2004; Zimprich et al. 2004; Higashi et al. 2007a; Higashi et al. 2007b; Melrose et al. 2006; Simon-Sanchez et al. 2006; Westerlund et al. 2008). It is also known that LRRK2 expression is much higher in the spleen, lung, kidney, and testis than in other organs, including the brain (Westerlund et al. 2008; Biskup et al. 2007; Larsen and Madsen 2009; Maekawa et al. 2010).
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
2015, Neurobiology of Disease